An emerging target for chronic kidney disease treatment – DNA-PKcs

By Dr. Priyom Bose, PhD
Around 10% of the global population is affected by chronic kidney disease (CKD). The risk of CKD progressing into end-stage renal disease (ESRD) is exceptionally high, which requires dialysis or kidney transplantation. At present, there is no effective treatment for CKD is available. Hence, there is an urgent need to uncover the underlying pathological mechanisms of CKD to help formulate effective treatment strategies to prevent and cure the disease. A recent Nature Communications study suggested that DNA-PKcs could be a potential target for treating CKD. Read more in News Medical Life Sciences.